The application of tegrilol, a new chemical drug of class 3.1 in Kelun Pharmaceutical Co., Ltd., has been accepted
-
Last Update: 2014-10-21
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Tegrilol is a new and selective small molecule anticoagulant developed by AstraZeneca to reduce cardiovascular death and heart attack in patients with acute coronary syndrome (ACS) In July 2011, it was approved by FDA to be listed, and in November 2012, it was approved to be imported into China Compared with clopidogrel, a popular antiplatelet drug, tegrarol is more effective and safe There is only one original manufacturer with production approval for this product in China, but at the same time, there are 8 domestic enterprises including Hengrui Pharmaceutical (600276 SH), Qilu pharmaceutical, etc Industry insiders pointed out that the pharmaceutical preparation has been approved for production by import enterprises, which is a generic drug, so it is directly applied for production, but after approval, it needs to do bioequivalence test or clinical Since 2013, the new drug research and development of Kelun pharmaceutical industry has been promoted rapidly According to the product approval in the company's annual report, 42 class a projects have been applied, including 20 production applications The R & D progress has been scheduled to 2020 In 2013, R & D investment exceeded 400 million yuan, up 99.74% year on year, accounting for 5.86% of operating revenue.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
